CD4 and neoplasm: Compared with treatment-naive tumor lesions, more intra-tumoral NK/NKT and CD4+ T cells were found in neoadjuvant non-MPR and MPR tumor lesions (NK/NKT: 2.36% versus 5.71% versus 5.72%; CD4+ T cells: 7.23% versus 14.05% versus 13.24%).